Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Enhancement of safety and immunogenicity of the Chinese Hu191 measles virus vaccine by alteration of the S-adenosylmethionine (SAM) binding site in the large polymerase protein.
Virology ( IF 3.7 ) Pub Date : 2018-03-15 , DOI: 10.1016/j.virol.2018.02.022 Yilong Wang 1 , Rongxian Liu 1 , Mijia Lu 2 , Yingzhi Yang 1 , Duo Zhou 3 , Xiaoqiang Hao 1 , Dongming Zhou 3 , Bin Wang 4 , Jianrong Li 2 , Yao-Wei Huang 4 , Zhengyan Zhao 5
Virology ( IF 3.7 ) Pub Date : 2018-03-15 , DOI: 10.1016/j.virol.2018.02.022 Yilong Wang 1 , Rongxian Liu 1 , Mijia Lu 2 , Yingzhi Yang 1 , Duo Zhou 3 , Xiaoqiang Hao 1 , Dongming Zhou 3 , Bin Wang 4 , Jianrong Li 2 , Yao-Wei Huang 4 , Zhengyan Zhao 5
Affiliation
The live-attenuated measles virus (MV) vaccine based on the Hu191 strain has played a significant role in controlling measles in China. However, it has considerable adverse effects that may cause public health burden. We hypothesize that the safety and efficacy of MV vaccine can be improved by altering the S-adenosylmethionine (SAM) binding site in the conserved region VI of the large polymerase protein. To test this hypothesis, we established an efficient reverse genetics system for the rMV-Hu191 strain and generated two recombinant MV-Hu191 carrying mutations in the SAM binding site. These two mutants grew to high titer in Vero cells, were genetically stable, and were significantly more attenuated in vitro and in vivo compared to the parental rMV-Hu191 vaccine strain. Importantly, both MV-Hu191 mutants triggered a higher neutralizing antibody than rMV-Hu191 vaccine and provided complete protection against MV challenge. These results demonstrate its potential for an improved MV vaccine candidate.
更新日期：2018-03-15
京公网安备 11010802027423号